Spiral Flow(TM) Grafts Enhance Patient Outcomes

Date: Jul-12-2012New Paper Published in the Prestigious 'Annals of Vascular Surgery'

The medium term results of a 'First in Man' structured registry study are due to be
published in the October issue of the Annals of Vascular Surgery. This significant paper
describes a 40 patient, 10 centre study by leading vascular surgeons and doctors on
patients with peripheral arterial disease needing an above-the-knee or below-the-knee
bypass graft.

Peripheral arterial disease affects up to 20% of people over the age of 70. Patients
are at high risk for cardiovascular events in the future, especially those needing bypass
surgery. Improvements in bypass surgery techniques and devices are therefore very
significant and a large number of people could benefit.

This study demonstrates the
validity of the concept of Spiral Laminar Flow(TM). It shows patient outcomes equivalent
to, or exceeding, any known prosthetic grafts, including Heparin bonded grafts.

Vascular Flow Technologies is a medical device company operating within the peripheral
vascular market. Its revolutionary and unique Spiral Laminar Flow(TM) technology
re-establishes natural blood flow patterns in peripheral vascular and arteriovenous grafts
- helping to keep damaged blood vessels open for longer and improving outcomes for
patients.

Bill Allan, CEO, says, "We are very pleased to see this high quality study published
in a prestigious journal and are encouraged by the key findings within the paper. It's
clear that Spiral Flow(TM) Grafts enhance patient outcomes. We will continue to develop
more clinical experience and data sets and look forward to wider awareness of the true
impact of our Spiral Flow(TM) products on patients' lives."

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.